Job Research Foundation Announces Second Round of Funding: $400,000 in Grants Available to Researchers Investigating Causes/Treatments of Rare Multisystem Immunodeficiency Disorder
(NEW YORK CITY, NY, July 24, 2019) – The Job Research Foundation, which seeks to help find a cure for Job Syndrome by providing the scientific community with additional opportunities to further research into the rare multisystem immunodeficiency disorder, has announced the second round of grant funding. There will be two grants in the amount of $200,000 each. The grants will be awarded to scientific researchers who are investigating the causes of, and treatments for, Job Syndrome. Grant applications can be found online at www.jobresearchfoundation.org . Deadline to apply is October 17, 2019.
“Our long-term goal is to help advance research to find a cure for Job Syndrome,” said Ted Lavin, co-founder of The Job Research Foundation. “In the short term, we hope the research will improve the treatments for patients suffering from Job Syndrome. These grants are meant to make both goals a reality as soon as possible.”
In 2018, Job Research Foundation awarded four grants in the first round of funding to researchers from Australia, Spain, Germany, and the United States.
Special consideration will be given to research focused on Job Syndrome and Pulmonary Function. Previous applicants can apply in subsequent years to extend their research. The application process is open to researchers world-wide and awardees will be notified in early November.
The Job Research Foundation seeks to not only help find a cure for Job Syndrome by providing the scientific community with additional opportunities to further research into the rare multisystem immunodeficiency disorder, but also hopes that investigators will research treatments to help those suffering with Job Syndrome.
Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), was discovered in 1966 and is a multisystem immunodeficiency disorder found in males and females worldwide.